Replies to post #34067 on OncoSec Medical Inc (ONCSQ)

[Titan V]

And if in fact it lessens drastically the adverse events, while improving results with that slight increase in dosage and incorporation of IL-12, there will be no hesitation in moving forward and using the ImmunoPulse platform in a combination that might already be approved using pembrolizumab.

Interesting point Guti. I have always wondered if an introduction of Immunopulse Il-12 to an approved combo treatment will require clinical trials from phase 2. I'm guessing it would.